Our Pricing

Your Complete Guide to Criteria For NHS Mounjaro

Understanding the criteria for NHS Mounjaro UK is essential if you're considering this weight loss treatment. While NHS access remains highly restricted due to limited funding and strict eligibility thresholds, private prescription options through registered UK pharmacies like Cured Pharmacy offer an accessible alternative for patients who don't meet NHS criteria or face lengthy waiting lists.

Current NHS Mounjaro Eligibility Criteria UK

The criteria for NHS Mounjaro are determined by NICE (National Institute for Health and Care Excellence) guidance and local Integrated Care Board (ICB) funding decisions. As of 2025, NHS Mounjaro prescriptions are typically restricted to patients with a BMI of 35 kg/m² or above (or 32.5 kg/m² for people from Black, Asian, and minority ethnic backgrounds) who also have at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea [1].

Even when patients meet these clinical thresholds, NHS access remains severely limited. Many ICBs have paused new Mounjaro prescriptions entirely due to budget constraints and supply prioritisation for existing diabetes patients. Waiting lists in some regions exceed 12-18 months, and referral pathways often require multiple failed attempts with other weight loss interventions first [2].

It's important to note that meeting the BMI criteria alone does not guarantee NHS prescription. Your GP must refer you to a specialist weight management service, where a multidisciplinary team assesses your suitability. This typically includes dietary assessment, physical activity evaluation, psychological screening, and documentation of previous weight loss attempts over at least 6-12 months.

Why NHS Mounjaro Access Remains So Restricted

The primary barrier to NHS Mounjaro availability is cost. Tirzepatide represents a significant financial commitment for already-stretched NHS budgets, with annual treatment costs substantially higher than older weight loss medications like orlistat. NICE guidance acknowledges Mounjaro's superior efficacy — clinical trials demonstrated average weight reductions of 20-22.5% over 72 weeks — but cost-effectiveness assessments have led most ICBs to implement strict rationing [1][3].

Supply chain constraints have further complicated NHS access. Manufacturer Eli Lilly has prioritised existing diabetes patients and markets with less restrictive reimbursement pathways. This has created a two-tier system where private patients can access Mounjaro relatively easily through registered online pharmacies, while NHS patients face indefinite delays despite meeting clinical criteria.

Additionally, the NHS prioritises a 'stepped care' approach, requiring patients to trial older, cheaper medications first. This means even eligible patients must typically demonstrate inadequate response to orlistat, lifestyle interventions, or other GLP-1 receptor agonists before Mounjaro is considered — a process that can extend timelines by 12-24 months.

Regional Variation in NHS Prescribing

NHS Mounjaro availability varies dramatically across the UK. Some ICBs in England have completely suspended new prescriptions, while others maintain small quotas allocated through specialist obesity clinics. Scotland, Wales, and Northern Ireland follow separate guidance, with most health boards implementing even stricter criteria than NICE recommendations. Before pursuing an NHS referral, check your local ICB's current formulary status and prescribing policy, as these change frequently based on budget cycles.

Private Mounjaro Prescription Criteria in the UK

Private prescription pathways through UK-registered pharmacies like Cured Pharmacy follow MHRA licensing criteria rather than NHS funding restrictions. To receive a private Mounjaro prescription, you typically need a BMI of 30 kg/m² or above (or 27 kg/m² with a weight-related comorbidity), which is more accessible than NHS thresholds [4].

During your online clinical assessment, a UK prescriber will evaluate your medical history, current medications, contraindications, and weight loss goals. The consultation considers factors such as previous weight loss attempts, cardiovascular health, history of pancreatitis or thyroid conditions, and any medications that might interact with tirzepatide. This assessment typically takes under 3 minutes to complete and is provided free of charge at Cured Pharmacy.

Private prescription offers significant advantages beyond lower BMI thresholds. There are no waiting lists, no requirement to fail other treatments first, and no need for specialist referrals. Treatment can begin within 24-48 hours of approval, with discreet delivery directly to your address. Cured Pharmacy supplies genuine UK-licensed Mounjaro KwikPens from £135.00 with transparent pricing shown before your consultation.

Who Cannot Take Mounjaro Privately

Certain medical conditions preclude Mounjaro use regardless of prescription route. Absolute contraindications include personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, severe gastrointestinal disease, and pregnancy or breastfeeding. Patients with a history of pancreatitis, severe renal impairment, or diabetic retinopathy require careful risk-benefit assessment. Your UK prescriber will review these factors during consultation to ensure Mounjaro is safe and appropriate for you [4].

How Mounjaro Works: The Science Behind Tirzepatide

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed for weight management in the UK. Unlike single-pathway medications such as semaglutide (Wegovy) or liraglutide (Saxenda), tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual mechanism produces more pronounced effects on appetite suppression, glucose metabolism, and energy expenditure [1].

In the landmark SURMOUNT-1 trial, patients without diabetes achieved average weight reductions of 15.0% (5mg dose), 19.5% (10mg dose), and 20.9% (15mg dose) over 72 weeks. More impressively, 50-57% of participants on the highest doses achieved at least 20% total body weight loss — outcomes previously seen only with bariatric surgery [1]. The SURMOUNT-2 trial in patients with type 2 diabetes showed similarly robust results, with average reductions of 12.8% to 15.7% depending on dose [3].

Tirzepatide works by slowing gastric emptying, reducing appetite through central nervous system pathways, and improving insulin sensitivity. Patients typically report reduced hunger, earlier satiety, and decreased food cravings within the first 2-4 weeks of treatment. The medication is administered as a once-weekly subcutaneous injection, with doses gradually escalated every 4 weeks to minimise gastrointestinal side effects.

Mounjaro vs NHS-Available Weight Loss Treatments

Understanding how Mounjaro compares to NHS-available alternatives helps contextualise the strict criteria for NHS Mounjaro prescriptions. Orlistat, the most commonly prescribed NHS weight loss medication, works by blocking fat absorption in the gut and produces average weight loss of 3-5% over 12 months — substantially less than tirzepatide's 15-22.5% reductions [2][5].

Wegovy (semaglutide) represents the closest NHS comparator to Mounjaro, though it remains subject to similar access restrictions. The STEP trials demonstrated average weight loss of 12.4-14.9% with semaglutide 2.4mg over 68 weeks — clinically significant but still lower than tirzepatide outcomes in head-to-head comparisons [2][6]. Some ICBs preferentially fund Wegovy over Mounjaro due to lower acquisition costs, despite the efficacy difference.

For patients who cannot access NHS Mounjaro, private prescription offers a range of evidence-based alternatives. At Cured Pharmacy, Wegovy is available with competitive UK pricing, Saxenda provides a daily injection option for those preferring smaller, more frequent doses, and orlistat-based treatments offer non-injection alternatives. Your UK prescriber can recommend the most appropriate option based on your clinical profile, preferences, and budget.

Treatment Duration and Maintenance

Both NHS and private Mounjaro prescriptions require ongoing monitoring and review. NICE guidance recommends discontinuing treatment if patients fail to achieve at least 5% weight loss after 6 months at therapeutic dose, though private prescribers may apply more individualised criteria. Long-term data suggests many patients require continued treatment to maintain weight loss, as discontinuation often leads to weight regain. This reality makes sustainable pricing and reliable supply critical considerations when choosing between NHS waiting lists and private prescription pathways.

Getting Started with Mounjaro at Cured Pharmacy

If you don't meet the criteria for NHS Mounjaro or face prohibitive waiting times, private prescription through Cured Pharmacy offers a straightforward alternative. Our process begins with a free online consultation completed in under 3 minutes, where you'll provide medical history, current medications, and weight management goals. A UK-registered prescriber reviews your assessment, typically within 24 hours, and determines whether Mounjaro or an alternative treatment is most appropriate.

Once approved, your prescription is dispensed by our GPhC-registered pharmacy (registration 9012511) under the supervision of Superintendent Pharmacist Tarun Kumar (GPhC 2233073). We supply only genuine UK-licensed Mounjaro KwikPens from £135.00 with all pricing displayed transparently before consultation. Delivery is 100% discreet, with no external branding or product descriptions on packaging.

Cured Pharmacy provides ongoing support throughout your treatment journey. You'll receive clear injection technique guidance, side effect management advice, and access to our clinical team for questions or concerns. Repeat prescriptions are streamlined through your online account, and we monitor supply closely to ensure continuity of care. Our lowest price guarantee means you're getting competitive UK pricing without compromising on pharmaceutical standards or clinical oversight.

What to Expect During Treatment

Mounjaro treatment follows a structured dose escalation schedule, starting at 2.5mg weekly for 4 weeks, then increasing to 5mg, 7.5mg, 10mg, 12.5mg, and potentially 15mg based on tolerability and response. Most patients experience mild gastrointestinal side effects (nausea, diarrhoea, constipation) during the first 4-8 weeks, which typically resolve as your body adjusts. Taking the injection on the same day each week, staying well-hydrated, and eating smaller, lower-fat meals can minimise these effects. Your prescriber will provide comprehensive guidance on managing side effects and optimising results through lifestyle modifications alongside medication [4].

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., ... & Bunck, M. C. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
3. Garvey, W. T., Frias, J. P., Jastreboff, A. M., le Roux, C. W., Sattar, N., Aizenberg, D., ... & Bunck, M. C. (2023). Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet, 402(10402), 613–626. https://doi.org/10.1016/S0140-6736(23)01200-X
4. Electronic Medicines Compendium. (2024). Mounjaro 2.5 mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC). Medicines and Healthcare products Regulatory Agency. Retrieved from https://www.medicines.org.uk/emc/product/14042/smpc
5. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (CG189). NICE Clinical Guideline. Retrieved from https://www.nice.org.uk/guidance/cg189
6. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., ... & Sørrig, R. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals, and outcomes described in clinical trials represent averages and may not reflect your personal experience.